The results showed that the average mRNA levels of AURKB in BRCA2-deficient patient samples were significantly lower than those in BRCA2-proficient patient samples, especially in BRCA2-deficient prostate cancer patient samples (Figure 6A and Supplemental Figure 6A). This evidence concerns the gene BRCA2 and prostate cancer.